Investigating the Prevalence of Comorbidity in Multiple Sclerosis Clinical Trial Populations.
Salter AmberSamantha LanciaKaarina KowalecKathryn C FitzgeraldKathryn C FitzgeraldPublished in: Neurology (2024)
Individuals with comorbidities are included in clinical trials, although they may still be underrepresented compared with the general MS population. Given the comorbidity prevalence in the trial populations and studies suggesting an association of comorbidities with disease activity, comorbidity may influence outcomes in clinical trials.
Keyphrases
- clinical trial
- disease activity
- multiple sclerosis
- phase ii
- systemic lupus erythematosus
- rheumatoid arthritis
- phase iii
- risk factors
- study protocol
- rheumatoid arthritis patients
- ankylosing spondylitis
- open label
- double blind
- juvenile idiopathic arthritis
- mass spectrometry
- white matter
- genetic diversity
- adipose tissue
- skeletal muscle
- glycemic control
- case control